United States - English - NLM (National Library of Medicine)

bryant ranch prepack - rivastigmine (unii: pki06m3iw0) (rivastigmine - unii:pki06m3iw0) - rivastigmine transdermal system is indicated for the treatment of dementia of the alzheimer's type (ad). efficacy has been demonstrated in patients with mild, moderate, and severe alzheimer's disease. rivastigmine transdermal system is indicated for the treatment of mild-to-moderate dementia associated with parkinson's disease (pdd). rivastigmine transdermal system is contraindicated in patients with: - known hypersensitivity to rivastigmine, other carbamate derivatives, or other components of the formulation [see description (11)] . - previous history of application site reactions with rivastigmine transdermal patch suggestive of allergic contact dermatitis [see warnings and precautions (5.3)] . isolated cases of generalized skin reactions have been described in postmarketing experience [see adverse reactions (6.2)] . risk summary there are no adequate data on the developmental risks associated with the use of rivastigmine transdermal system in pregnant women. in animals, no adverse effects on embryo-fetal d

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - rivastigmine (unii: pki06m3iw0) (rivastigmine - unii:pki06m3iw0) - rivastigmine transdermal system is indicated for the treatment of dementia of the alzheimer's type (ad). efficacy has been demonstrated in patients with mild, moderate, and severe alzheimer's disease. rivastigmine transdermal system is indicated for the treatment of mild-to-moderate dementia associated with parkinson's disease (pdd). rivastigmine transdermal system is contraindicated in patients with: - known hypersensitivity to rivastigmine, other carbamate derivatives, or other components of the formulation [see description (11)] . - previous history of application site reactions with rivastigmine transdermal patch suggestive of allergic contact dermatitis [see warnings and precautions (5.3)] . isolated cases of generalized skin reactions have been described in postmarketing experience [see adverse reactions (6.2)] . risk summary there are no adequate data on the developmental risks associated with the use of rivastigmine transdermal system in pregnant women. in animals, no adverse effects on embryo-fetal d

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - rivastigmine (unii: pki06m3iw0) (rivastigmine - unii:pki06m3iw0) - rivastigmine transdermal system is indicated for the treatment of dementia of the alzheimer's type (ad). efficacy has been demonstrated in patients with mild, moderate, and severe alzheimer's disease. rivastigmine transdermal system is indicated for the treatment of mild-to-moderate dementia associated with parkinson's disease (pdd). rivastigmine transdermal system is contraindicated in patients with: - known hypersensitivity to rivastigmine, other carbamate derivatives, or other components of the formulation [see description (11)] . - previous history of application site reactions with rivastigmine transdermal patch suggestive of allergic contact dermatitis [see warnings and precautions (5.3)] . isolated cases of generalized skin reactions have been described in postmarketing experience [see adverse reactions (6.2)] . risk summary there are no adequate data on the developmental risks associated with the use of rivastigmine transdermal system in pregnant women. in animals, no adverse effects on embryo-fetal d

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - rivastigmine (unii: pki06m3iw0) (rivastigmine - unii:pki06m3iw0) - rivastigmine transdermal system is indicated for the treatment of dementia of the alzheimer's type (ad). efficacy has been demonstrated in patients with mild, moderate, and severe alzheimer's disease. rivastigmine transdermal system is indicated for the treatment of mild-to-moderate dementia associated with parkinson's disease (pdd). rivastigmine transdermal system is contraindicated in patients with: - known hypersensitivity to rivastigmine, other carbamate derivatives, or other components of the formulation [see description (11)] . - previous history of application site reactions with rivastigmine transdermal patch suggestive of allergic contact dermatitis [see warnings and precautions (5.3)] . isolated cases of generalized skin reactions have been described in postmarketing experience [see adverse reactions (6.2)] . risk summary there are no adequate data on the developmental risks associated with the use of rivastigmine transdermal system in pregnant women. in animals, no adverse effects on embryo-fetal d

Canada - English - Health Canada

mylan pharmaceuticals ulc - rivastigmine - patch - 4.6mg - rivastigmine 4.6mg - parasympathomemetic (cholinergic) agents

Canada - English - Health Canada

mylan pharmaceuticals ulc - rivastigmine - patch - 9.5mg - rivastigmine 9.5mg - parasympathomemetic (cholinergic) agents

United States - English - NLM (National Library of Medicine)

mckesson corporation dba sky packaging - rivastigmine tartrate (unii: 9iy2357jpe) (rivastigmine - unii:pki06m3iw0) - rivastigmine 1.5 mg - rivastigmine tartrate capsules are indicated for the treatment of mild-to-moderate dementia of the alzheimer's type (ad). rivastigmine tartrate capsules are indicated for the treatment of mild-to-moderate dementia associated with parkinson’s disease (pd). rivastigmine tartrate capsules are contraindicated in patients with: - known hypersensitivity to rivastigmine, other carbamate derivatives or other components of the formulation [see description (11) ]. - a previous history of application site reaction with rivastigmine transdermal patch suggestive of allergic contact dermatitis, in the absence of negative allergy testing [see warnings and precautions (5.2)] . isolated cases of generalized skin reactions have been described in postmarketing experience [see adverse reactions (6.2)]

United States - English - NLM (National Library of Medicine)

carilion materials management - rivastigmine tartrate (unii: 9iy2357jpe) (rivastigmine - unii:pki06m3iw0) - rivastigmine 1.5 mg - rivastigmine tartrate capsules are indicated for the treatment of mild to moderate dementia of the alzheimer's type. rivastigmine tartrate capsules are indicated for the treatment of mild to moderate dementia associated with parkinson's disease. rivastigmine tartrate capsules are contraindicated in patients with: - known hypersensitivity to rivastigmine, other carbamate derivatives or other components of the formulation [see description (11)]. - a previous history of application site reaction with rivastigmine transdermal patch suggestive of allergic contact dermatitis, in the absence of negative allergy testing [see warnings and precautions (5.2)] . isolated cases of generalized skin reactions have been described in postmarketing experience [see adverse reactions (6.2)] . pregnancy category b there are no adequate and well-controlled studies in pregnant women. reproduction studies conducted in pregnant rats and rabbits at oral doses up to 2.3 mg base/kg/day, or 2 (rat) and 4 (rabbit) times the maximum recomm

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - rivastigmine, quantity: 27 mg - drug delivery system, transdermal - excipient ingredients: acrylates copolymer; ethyl acetate; methylated trimethylated silica; hexane; 2-ethylhexyl acrylate; methyl acrylate; acrylic acid; acrylates/ethylhexyl acrylate copolymer - rivastigmine gxp patch is indicated for the treatment of patients with mild, moderate and severe dementia of the alzheimer?s type.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - rivastigmine, quantity: 27 mg - drug delivery system, transdermal - excipient ingredients: acrylates copolymer; ethyl acetate; methylated trimethylated silica; hexane; 2-ethylhexyl acrylate; methyl acrylate; acrylic acid; acrylates/ethylhexyl acrylate copolymer - rivastigmine aml patch is indicated for the treatment of patients with mild, moderate and severe dementia of the alzheimer?s type.